

Frequently Asked Questions (FAQ)

Background Information on the share structure

The shares of BioNTech SE are registered shares (ORD). The conversion into a Societas Europaea (SE) took place on March 8, 2019. The registered shares are not listed on a stock exchange.

In October 2019, BioNTech SE went public on the U.S. Nasdaq Global Select Market. The decision to list on the U.S. stock exchange was made against the background of securing the best possible access to capital for the Company's growth plans which is seen in the highly specialized biotechnology market in the U.S.

As a foreign private issuer, BioNTech has issued American Depositary Shares (ADS). An ADS is an equity share of a non-U.S. company that is held by a U.S. depository bank. The U.S. depository bank issues American depositary receipts (ADRs), which are U.S dollar denominated certificates, and evidence of ownership of ADSs. The ADRs represent a certain number of deposited shares in a foreign company and are traded on the U.S. capital market like shares. Each ADS of BioNTech represents one ordinary share.

The American Depositary Shares (ADS) of BioNTech SE are traded on the stock exchange.

ADSs carry certain rights set forth in the Depositary Agreement and are specifically designed to facilitate trading of non-U.S. securities on U.S. exchanges. The FORM F-1 Registration Statement explains the rights in detail.

Overview:

Structure	Sponsored Level 3 ADS
Ratio (ADS:ORD)	1:1
Trading Location	Nasdaq; Germany: OTC (over-the-counter) market
Ticker Symbol	BNTX
ISIN	US09075V1026 (WKN: A2PSR2)

The U.S. depository bank is generally responsible for forwarding the documents for the Annual General Meeting to the ADS holders. In the case of BioNTech, this is the Bank of New York Mellon. ADS holders are typically informed about the Annual General Meeting by the Bank of New York Mellon via the respective banks or brokers. The Bank of New York Mellon, also via the ADS holders' banks or brokers, collects the voting instructions from, and distributes any dividend to, the ADS holders.

How can you as an ADS holder exercise your rights at the Annual General Meeting?

In addition to the distribution of documents by Bank of New York Mellon and the bank/broker in the relevant jurisdiction, all relevant Annual General Meeting documents are available on the Company's website at

<https://investors.biontech.de/agm/agm-2023>

The invitation convening the Annual General Meeting has been published in the "Bundesanzeiger".

BioNTech's AGM will take place on Thursday, May 25, 2023, 14:00 (CEST) at the Company's offices at An der Goldgrube 12, 55131 Mainz, Germany.

Please note that holders of ADSs are not entitled to attend the AGM in-person.

It is intended to broadcast the introductory remarks of the Chairman of the meeting and the subsequent speeches of the Chief Executive Officer and the Chief Financial Officer to its shareholders, ADS holders and interested members of the public live via video and audio transmission at the following address:

<https://investors.biontech.de/agm/agm-2023>

Please note that ADS holders will not be able to vote directly on Annual General Meeting agenda items during the Annual General Meeting. Bank of New York Mellon, as the U.S. depository bank, and the bank / broker in the relevant jurisdiction are responsible for sending out the Annual General Meeting documents for the issuance of voting instructions as well as information on applicable deadlines for ADS holders.

In addition, we are giving ADS holders the opportunity, on a voluntary basis, to submit questions on the items on the agenda of the Annual General Meeting no later than midnight (CEST) on Tuesday, 23 May 2023, to the extent that shareholders may request such information at the Annual General Meeting. Any questions must be submitted to the following e-mail address: HV@biontech.de

Further questions related to ADSs should be directed to BNY Mellon Shareowner Services at:

BNY Mellon Shareowner Services
shrrelations@cpushareownerservices.com
Telephone: +1 201 680 6825
and toll free in the USA: +1 888 269 2377

For any other questions related to the AGM please contact:

Computershare Operations Center
Telephone: +49 89 30903 6413
Email: HV@biontech.de